JAGXJaguar HealthJAGX info
$1.10info-8.33%24h
Global rank24587
Market cap$55.83M
Change 7d0.00%
YTD Performance623.68%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Jaguar Health (JAGX) Stock Overview

    Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.

    JAGX Stock Information

    Symbol
    JAGX
    Address
    200 Pine StreetSan Francisco, CA 94104United States
    Founded
    -
    Trading hours
    -
    Website
    https://jaguar.health
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    415 371 8300

    Jaguar Health (JAGX) Price Chart

    -
    Value:-

    Jaguar Health Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $1.10
    N/A
    Market Cap
    $55.83M
    N/A
    Shares Outstanding
    50.76M
    N/A
    Employees
    60.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org